

d his

(FILE 'HOME' ENTERED AT 18:06:36 ON 29 JAN 2004)

FILE 'CAPLUS' ENTERED AT 18:06:46 ON 29 JAN 2004

L1 8 S (ALBUMIN (3W) (CONUGATE OR (FUSION PROTEIN))) AND (STABILI  
 L2 61 S (ALBUMIN (3W) (CONUGATE OR (FUSION PROTEIN))) NOT ROSEN,C

=&gt; d bib,abs,kwic 41,43,46,48,51,53,55,56

L2 ANSWER 41 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full  
Text

AN 1998:106031 CAPLUS

DN 128:166373

TI Fusion polypeptides comprising an IgE-binding domain and a human serum albumin component, and their diagnostic and therapeutic uses for allergy

IN Digan, Mary Ellen; Lake, Philip; Gram, Hermann

PA Novartis A.-G., Switz.; Digan, Mary Ellen; Lake, Philip; Gram, Hermann

SO PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9804718</u>	A1	19980205	<u>WO 1997-EP4066</u>	19970725
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>US 6423512</u>	B1	20020723	<u>US 1997-897956</u>	19970721
<u>AU 9742025</u>	A1	19980220	<u>AU 1997-42025</u>	19970725
<u>AU 722069</u>	B2	20000720		
<u>ZA 9706666</u>	A	19990125	<u>ZA 1997-6666</u>	19970725
<u>EP 917581</u>	A1	19990526	<u>EP 1997-940030</u>	19970725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
<u>BR 9710605</u>	A	19990817	<u>BR 1997-10605</u>	19970725
<u>CN 1229439</u>	A	19990922	<u>CN 1997-197659</u>	19970725
<u>JP 2000516089</u>	T2	20001205	<u>JP 1998-508504</u>	19970725
<u>RU 2209211</u>	C2	20030727	<u>RU 1999-103326</u>	19970725
<u>NO 9900328</u>	A	19990219	<u>NO 1999-328</u>	19990125
<u>KR 2000029563</u>	A	20000525	<u>KR 1999-700621</u>	19990125
<u>PRAI US 1996-690216</u>	A	19960726		
<u>US 1996-22689P</u>	P	19960726		
<u>WO 1997-EP4066</u>	W	19970725		

AB Disclosed is a fusion polypeptide comprising a IgE-binding domain and a human serum albumin (HSA) for use as a diagnostic and therapeutic agent for allergy. Systematically administered IgE-binding polypeptide will bind to serum IgE as well as to circulating auto-antibodies against IgE receptor, FcεRIα, preventing them from binding to cell-bound FcεRIα, nd thus preventing and/or inhibiting allergic reactions. The fusion polypeptide may be prep'd. into a dimeric form which is more efficient on binding to IgE than the monomers. Cloning of cDNA for HSA and IgER, prepn. of fusion construct R-H-R/SK#50 encoding dimeric pre-IgER-L1-HSA II-L2-IgER, prepn. of plasmid pXMT3-RIα-HSA-

RI $\alpha$  for the expression of the fusion construct, and expression of the chimeric gene in CHO cells were shown. They are useful in the prevention and/or treatment of IgE-mediated allergic diseases and related disorders such as atopic dermatitis, atopic asthma and chronic urticaria. Pharmaceutical compn. contg. the fusion polypeptide and use of a polynucleotide encoding the fusion polypeptide for gene therapy are claimed.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT **Albumins**, biological studies

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(serum, **fusion protein** with human IgE receptor;  
fusion polypeptides comprising IgE-binding domain and a human serum albumin component, and diagnostic and therapeutic uses for allergy)

L2 ANSWER 43 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text References

AN 1997:510221 CAPLUS

DN 127:120751

TI Manufacture of growth hormone as a fusion protein with serum albumin to increase storage- and serum-stability

IN Ballance David James

PA Delta Biotechnology Limited, UK; Ballance, David James

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9724445	A1	19970710	WO 1996-GB3164	19961219
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2240292	AA	19970710	CA 1996-2240292	19961219
AU 9711649	A1	19970728	AU 1997-11649	19961219
AU 715210	B2	20000120		
EP 870039	A1	19981014	EP 1996-942515	19961219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1207131	A	19990203	CN 1996-199466	19961219
CN 1119421	B	20030827		
JP 2000502901	T2	20000314	JP 1997-524098	19961219
US 2003104578	A1	20030605	US 2001-984010	20011026
PRAI GB 1995-26733	A	19951230		
WO 1996-GB3164	W	19961219		
US 1998-91873	B1	19980625		
AB				
Fusion proteins of albumin and growth hormone, or fusions of variants of either, are secreted by yeast and have increased serum and storage stability. The two domains of the fusion protein may be linked by a peptide cleavable by an endogenous proteinase, such as KEX2. The construction of chimeric genes for expression in <i>Saccharomyces cerevisiae</i> using prior integrating or centromere vectors for expression with the INV2 or SUC2 signal sequences used to direct secretion is described.				

- IT Plasmid vectors  
(pHGH16, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH31, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH38, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH56, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH57, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH58, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH59, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH60, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH61, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH62, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)
- IT Plasmid vectors  
(pHGH63, chimeric gene for human serum **albumin fusion protein** with human growth hormone on; manuf. of growth hormone as fusion protein with serum albumin to increase storage- and serum-stability)

L2 ANSWER 46 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text	References
--------------	------------

AN 1996:504887 CAPLUS

DN 125:159781

TI Overexpression and stability of recombinant human chimeric protein (granulocyte macrophage colony stimulating factor/serum albumin) in E. coli

AU Zhu, Zhen-qi; Liu, Jin; Ma, Da-Long; Zhang, Ying-Mei; Wu, Yue-Hong; Song, Quan-Sheng; Di, Chun-Hui

CS Dep. of Immunology, Beijing Medical Univ., Beijing, 100083, Peop. Rep. China

SO Shengwu Huaxue Zazhi (1996), 12(3), 284-288  
CODEN: SHZAE4; ISSN: 1000-8543

PB Zhongguo Shengwu Huaxue Yu Fenzi Shengwu Xuehui

DT Journal

LA Chinese

AB A recombinant vector pMT-GM-HSA expressing the chimeric protein which contained the entire human granulocyte macrophage colony stimulating factor (GM-CSF) and domain 3 of human serum albumin (HSA) was constructed. The chimeric protein was expressed up to 32.6% of total protein in Escherichia coli. In vitro bioactivity anal. with TF-1 cell line showed that the fusion protein expressed a specific stimulating activity of  $1.04 \times 10^6$  U/mg on the proliferation of TF-1 cells. In vitro the GM-CSF/HSA fusion protein showed higher thermostability and storage stability than GM-CSF.

ST cloning granulocyte macrophage colony stimulating factor; **albumin** granulocyte factor **fusion protein** cloning

IT Escherichia coli  
(expression of human granulocyte macrophage colony stimulating factor/serum **albumin fusion protein** in Escherichia coli)

IT Albumins, preparation  
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)  
(fusion product with granulocyte macrophage colony stimulating factor; expression of human granulocyte macrophage colony stimulating factor/serum **albumin fusion protein** in Escherichia coli)

IT 83869-56-1DP, Granulocyte macrophage colony stimulating factor, fusion products with albumin  
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)  
(expression of human granulocyte macrophage colony stimulating factor/serum **albumin fusion protein** in Escherichia coli)

L2 ANSWER 48 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text References

AN 1996:97267 CAPLUS

DN 124:167504

TI **Albumin fusion proteins** with the biological activity of a foreign polypeptides and their preparation by insertion of functional domains into the albumin structure

IN Becquart, Jerome; Conseiller, Emmanuel; Guitton, Jean-Dominique; Hardy, Florence; Yeh, Patrice

PA Rhone-Poulenc Rorer S.A., Fr.

SO PCT Int. Appl., 46 pp  
CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9530759	A1	19951116	WO 1995-FR520	19950420
	W: CA, JP, US				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
FR 2719593 A1 19951110 FR 1994-5616 19940506  
FR 2719593 B1 19960531  
PRAI FR 1994-5616 19940506

AB Biol. active polypeptides that have the biol. active domains of a protein inserted into an albumin are manufd. for use in pharmaceuticals. The integration of the biol. active domains into the albumin structure is particularly advantageous when the protein of interest is too fragile to be used on its own. The protein is manufd. by expression of a chimeric gene encoding it. Preferred sites for integration of the peptide into the serum albumin framework are identified from the structure of human serum albumin.

TI **Albumin fusion proteins** with the biological activity of a foreign polypeptides and their preparation by insertion of functional domains into the albumin structure

ST **albumin fusion protein** biol active peptide; human serum **albumin fusion protein**; serum **albumin fusion protein** biol active

IT Kluyveromyces  
Saccharomyces cerevisiae  
(expression host; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)

IT Chemotactic factors  
(fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)

IT Animal growth regulators  
Antibodies  
Antigens  
Blood-coagulation factors  
Enzymes  
Hormones  
Interferons  
Lymphokines and Cytokines  
Receptors  
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)

IT **Albumins**, biological studies  
RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(fusion proteins; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)

IT Animal growth regulators  
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(CSF (cytostatic factor), fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)

IT Proteins, specific or class  
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(adhesive, fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity)

- of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Proteins, specific or class  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (antifungal, fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Proteins, specific or class  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (bactericidal, fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Animal growth regulators  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (bone morphogenetic proteins, fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Proteins, specific or class  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (extracellular matrix-assocd., fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Proteins, specific or class  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (fusion products, **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Lymphokines and Cytokines  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (migration-stimulating factor, fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)
- IT Proteins, specific or class  
 RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (motility, fusion proteins contg. biol. active domains of; **albumin fusion proteins** with biol. activity of foreign polypeptides and their prepn. by insertion of functional domains into albumin structure)

L2 ANSWER 51 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

AN 1993:618356 CAPLUS  
 DN 119:218356  
 TI New polypeptides having granulocyte colony stimulating activity, preparation thereof and pharmaceutical compositions containing said polypeptides  
 IN Yeh, Patrice  
 PA Rhone-Poulenc Rorer S.A., Fr.  
 SO PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9315211	A1	19930805	WO 1993-FR86	19930128
	W: CA, FI, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2686900	A1	19930806	FR 1992-1065	19920131
	FR 2686900	B1	19950721		
	EP 624200	A1	19941117	EP 1993-904130	19930128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 07503844	T2	19950427	JP 1993-512987	19930128
	US 5665863	A	19970909	US 1994-256938	19940727
	FI 9403564	A	19940729	FI 1994-3564	19940729
	NO 9402858	A	19940801	NO 1994-2858	19940801
PRAI	FR 1992-1065		19920131		
	WO 1993-FR86		19930128		

AB The title proteins comprise a portion of G-CSF fused to a stabilizing peptide or protein, the fusion protein possessing G-CSF activity. The stabilizing peptide or protein may be albumin, apolipoprotein, Ig, or transferrin. The fusion protein may be used to treat leukopenias and leukemias (no data) or as an immunostimulant. Plasmids encoding mature G-CSF fused to human serum albumin were prepd. Kluyveromyces lactis transformed with these plasmids produced the fusion proteins which were isolated and tested for activity. The serum albumin-G-CSF fusion had a 7-fold lower specific activity in vitro (stimulation of IL-3 dependent murine cell line proliferation) than G-CSF, but in vivo (stimulation of granulopoiesis in rat) the specific activities were identical.

IT Kluyveromyces lactis  
(expression in, of granulocyte colony-stimulating factor-human serum **albumin fusion protein cDNA**)

IT Plasmid and Episome  
(pYG1266 and pYG1302 and pYG1351, granulocyte colony-stimulating factor-human serum **albumin fusion protein** cDNA on, expression in Kluyveromyces lactis of)

L2 ANSWER 53 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text	References
--------------	------------

AN 1993:597279 CAPLUS

DN 119:197279

TI Fusion proteins of albumin with therapeutically active proteins, preparation thereof, and pharmaceutical composition containing said fusion proteins

IN Fleer, Reinhard; Fournier, Alain; Guitton, Jean Dominique; Jung, Gerard; Yeh, Patrice

PA Rhone-Poulenc Rorer S.A., Fr.

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9315199	A1	19930805	WO 1993-FR85	19930128
	W: CA, FI, JP, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2686899	A1	19930806	FR 1992-1064	19920131
	FR 2686899	B1	19950901		
	EP 624195	A1	19941117	EP 1993-904129	19930128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				

JP 07503368	T2	19950413	JP 1993-512986	19930128
JP 2003235589	A2	20030826	JP 2003-8385	19930128
FI 9403563	A	19940729	FI 1994-3563	19940729
NO 9402839	A	19940922	NO 1994-2839	19940729
US 5876969	A	19990302	US 1997-797689	19970131
US 2002151011	A1	20021017	US 2001-984186	20011029
US 2003022308	A1	20030130	US 2002-237667	20020910
US 2003036170	A1	20030220	US 2002-237708	20020910
US 2003036171	A1	20030220	US 2002-237866	20020910
US 2003036172	A1	20030220	US 2002-237871	20020910
US 2003082747	A1	20030501	US 2002-237624	20020910
PRAI FR 1992-1064	A	19920131		
JP 1993-512986	A3	19930128		
WO 1993-FR85	W	19930128		
US 1994-256927	B1	19940728		
US 1997-797689	A3	19970131		
US 1999-258532	B1	19990226		
US 2001-984186	A3	20011029		
AB	Novel biol. active proteins comprise fusion proteins between fragments of therapeutically active proteins and albumin or albumin variants. The novel fusion proteins are prepd. by expressing recombinant, chimeric genes for these proteins in suitable host cells. Plasmids encoding human serum albumin fused to von Willebrand factor, urokinase, G-CSF, and an Fv fragment of an Ig were prepd. The chimeric genes were expressed in Kluyveromyces lactis. The specific activity of the G-CSF fusion protein was ~7-fold less than native G-CSF in vitro, but in vivo the specific activities of these 2 forms of G-CSF were comparable.			
IT	Kluyveromyces Kluyveromyces lactis (biol. active <b>albumin fusion proteins</b> manuf. with)			
IT	Protein sequences (of <b>albumin fusion proteins</b> )			
IT	Deoxyribonucleic acid sequences (complementary, for <b>albumin fusion proteins</b> )			

L2 ANSWER 55 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text	References
AN 1991:557129 CAPLUS	
DN 115:157129	
TI Preparation of <b>albumin-viral receptor fusion proteins</b> for pharmacological use	
IN Becquart, Jerome; Fleer, Reinhard; Hirel, Philippe Herve; Klatzmann, David Robert; Landais, Didier; Mayaux, Jean Francois; Yeh, Patrice	
PA Rhone-Poulenc Sante, Fr.	
SO Eur. Pat. Appl., 66 pp. CODEN: EPXXDW	
DT Patent	
LA English	
FAN.CNT 1	

AN 1991:557129 CAPLUS

DN 115:157129

TI Preparation of **albumin-viral receptor fusion proteins** for pharmacological use

IN Becquart, Jerome; Fleer, Reinhard; Hirel, Philippe Herve; Klatzmann, David Robert; Landais, Didier; Mayaux, Jean Francois; Yeh, Patrice

PA Rhone-Poulenc Sante, Fr.

SO Eur. Pat. Appl., 66 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 413622	A1	19910220	EP 1990-402215	19900802
EP 413622	B1	19980211		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
FR 2650598	A1	19910208	FR 1989-10480	19890803
FR 2650598	B1	19940603		
ZA 9005953	A	19910424	ZA 1990-5953	19900730
CA 2022539	AA	19910204	CA 1990-2022539	19900802
CA 2022539	C	20010619		



<u>HU 55050</u>	A2	19910429	<u>HU 1990-4867</u>	19900802
<u>HU 215457</u>	B	19990128		
<u>AT 163197</u>	E	19980215	<u>AT 1990-402215</u>	19900802
<u>ES 2113854</u>	T3	19980516	<u>ES 1990-402215</u>	19900802
<u>AU 9060187</u>	A1	19910207	<u>AU 1990-60187</u>	19900803
<u>AU 635759</u>	B2	19930401		
<u>JP 03178998</u>	A2	19910802	<u>JP 1990-206680</u>	19900803
<u>JP 3315689</u>	B2	20020819		
<u>US 6165470</u>	A	20001226	<u>US 1998-4319</u>	19980108
<u>US 2003054554</u>	A1	20030320	<u>US 2002-73118</u>	20020212
<u>PRAI FR 1989-10480</u>	A	19890803		
<u>US 1990-561879</u>	B1	19900802		
<u>US 1992-955243</u>	B1	19921001		
<u>US 1993-121236</u>	B1	19930913		
<u>US 1994-295078</u>	B1	19940826		
<u>US 1995-479146</u>	B1	19950607		
<u>US 1998-4319</u>	A1	19980108		
<u>US 2000-551635</u>	B1	20000418		

AB **Albumin-viral receptor fusion proteins** are produced by recombinant cells. A plasmid encoding an **albumin-CD4 fragment fusion protein** was constructed. *Kluyveromyces lactis* transformed with this plasmid produced the fusion protein which was purified and characterized. The protein inhibited binding of HIV-1 to CE713 cells somewhat better than did intact CO4 and thereby reduced HIV-1 to CE713 infectivity. The half-life of this fusion protein in rabbit blood was 34 h (relative to 0.23 h for CD4 and 47 h for albumin itself).

TI Preparation of **albumin-viral receptor fusion proteins** for pharmacological use

AB **Albumin-viral receptor fusion proteins** are produced by recombinant cells. A plasmid encoding an **albumin-CD4 fragment fusion protein** was constructed. *Kluyveromyces lactis* transformed with this plasmid produced the fusion protein which was purified and characterized. The protein inhibited binding of HIV-1 to CE713 cells somewhat better than did intact CO4 and thereby reduced HIV-1 to CE713 infectivity. The half-life of this fusion protein in rabbit blood was 34 h (relative to 0.23 h for CD4 and 47 h for albumin itself).

ST **albumin virus receptor fusion protein; CD4 albumin fusion protein; HIV1 binding CD4 albumin fusion**

IT Protein sequences  
(of serum **albumin**-Cd4 fragment **fusion protein**)

IT *Kluyveromyces*  
*Kluyveromyces lactis*  
Yeast  
(serum **albumin-viral receptor fusion protein** manuf. with)

IT Virus, animal  
(human immunodeficiency 1, inhibitors of, serum **albumin-CD4 fragment fusion proteins** as)

IT 136250-81-2  
RL: BIOL (Biological study)  
(leucine zipper, serum **albumin-CD4 fragment fusion protein** fused to)

L2 ANSWER 56 OF 61 CAPLUS COPYRIGHT 2004 ACS on STN

Full Text	Citing References
--------------	----------------------

AN 1991:466184 CAPLUS

DN 115:66184

TI Fusion proteins containing N-terminal fragments of human serum albumin

IN Ballance, David James

PA Delta Biotechnology Ltd., UK  
 SO PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9013653	A1	19901115	WO 1990-GB650	19900426
	W: AU, FI, GB, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	AU 9055646	A1	19901129	AU 1990-55646	19900426
	AU 630450	B2	19921029		
	EP 470165	A1	19920212	EP 1990-907285	19900426
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04506598	T2	19921119	JP 1990-506978	19900426
	HU 61049	A2	19921130	HU 1990-4413	19900426
	CA 2015687	AA	19901029	CA 1990-2015687	19900427
	CA 2015687	C	20000829		
	ZA 9003237	A	19910327	ZA 1990-3237	19900427
	IL 94243	A1	19951031	IL 1990-94243	19900429
	GB 2246783	A1	19920212	GB 1991-19043	19910906
	GB 2246783	B2	19921014		
	US 5766883	A	19980616	US 1993-153799	19931117
PRAI	GB 1989-9916	A	19890429		
	WO 1990-GB650	A	19900426		
	US 1991-775952	B2	19911029		
	US 1992-847975	B1	19920306		

AB Recombinant fusion proteins comprising an N-terminus derived from human serum albumin (HSA) or an HSA variant fused to a C-terminus which is not HSA, e.g. a human fibronectin fragment, a CD4 fragment, platelet-derived growth factor, transforming growth factor  $\beta$ , a von Willebrand's factor fragment, or  $\alpha$ -1-antitrypsin. The HSA N-terminus favors secretion of the fusion proteins from eukaryotic cells. Plasmids encoding HSA 1-387 or HSA 1-195 fused to human fibronectin 585-1578 were prep'd. *Saccharomyces cerevisiae* transformed with these plasmids produced and secreted the fusion proteins.

ST **albumin** fibronectin **fusion protein** *Saccharomyces*

IT Protein sequences  
 (for **albumin**-fibronectin **fusion proteins**  
 of human)

IT *Saccharomyces cerevisiae*  
 (human serum **albumin** fragment-contg. **fusion**  
**proteins** manuf. with)

IT **Albumins**, biological studies  
 RL: BIOL (Biological study)  
 (human, **fusion proteins** contg., prodn. and  
 secretion with recombinant eukaryotic cells of)

IT Molecular cloning  
 (of **albumin**-fibronectin **fusion protein**  
 cDNA, in *Saccharomyces cerevisiae*)